Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL NASDAQ:FDMT NASDAQ:INBX NASDAQ:IVVD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$5.72-3.9%$5.85$3.79▼$14.60$313.75M-0.881.04 million shs326,664 shsFDMT4D Molecular Therapeutics$6.73-5.0%$4.93$2.23▼$17.41$314.43M2.83877,411 shs549,723 shsINBXInhibrx Biosciences$25.00$20.30$10.81▼$25.61$362M0.24106,024 shs54,622 shsIVVDInvivyd$0.56+7.1%$0.73$0.35▼$2.74$66.92M0.516.84 million shs2.54 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics0.00%-2.30%-15.24%+9.58%+4.75%FDMT4D Molecular Therapeutics0.00%-2.34%+55.14%+103.15%-52.61%INBXInhibrx Biosciences0.00%+7.16%+8.32%+94.40%+87.41%IVVDInvivyd0.00%-26.45%-33.75%-30.51%-48.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.3442 of 5 stars3.62.00.00.01.71.70.6FDMT4D Molecular Therapeutics2.0066 of 5 stars3.32.00.00.01.61.70.6INBXInhibrx Biosciences1.3783 of 5 stars0.03.00.04.62.01.70.0IVVDInvivyd3.9717 of 5 stars3.65.00.00.02.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.20Buy$22.00284.95% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40351.51% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AIVVDInvivyd 3.25Buy$3.18471.51% UpsideCurrent Analyst Ratings BreakdownLatest IVVD, FDMT, INBX, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.008/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform8/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $3.008/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)7/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,614.61N/AN/A$1.41 per share4.05FDMT4D Molecular Therapeutics$40K7,860.78N/AN/A$11.05 per share0.61INBXInhibrx Biosciences$200K1,810.00$119.05 per share0.21$9.23 per share2.71IVVDInvivyd$25.38M2.64N/AN/A$0.56 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A5.06N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)Latest IVVD, FDMT, INBX, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.017.047.04FDMT4D Molecular TherapeuticsN/A8.758.75INBXInhibrx Biosciences1.454.984.98IVVDInvivydN/A1.331.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%FDMT4D Molecular Therapeutics99.27%INBXInhibrx Biosciences82.46%IVVDInvivyd70.36%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%FDMT4D Molecular Therapeutics9.60%INBXInhibrx BiosciencesN/AIVVDInvivyd25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableINBXInhibrx Biosciences16614.48 millionN/AOptionableIVVDInvivyd100120.14 million89.63 millionOptionableIVVD, FDMT, INBX, and CADL HeadlinesRecent News About These CompaniesInvivyd Raises $53.5 Million in Public OfferingAugust 22 at 4:50 PM | tipranks.comInvivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional SharesAugust 22 at 1:23 PM | markets.businessinsider.comInvivyd, Inc. Closes Public Offering Raising Approximately $57.5 MillionAugust 22 at 12:31 PM | quiverquant.comQInvivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional SharesAugust 22 at 12:00 PM | globenewswire.comHC Wainwright Analysts Cut Earnings Estimates for InvivydAugust 22 at 7:21 AM | marketbeat.comHC Wainwright Forecasts Invivyd's Q3 Earnings (NASDAQ:IVVD)August 22 at 2:29 AM | americanbankingnews.comInsider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 18,512 Shares of StockAugust 21, 2025 | marketbeat.comInsider Selling: Invivyd (NASDAQ:IVVD) CFO Sells 20,013 Shares of StockAugust 21, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 20,013 SharesAugust 21, 2025 | marketbeat.comInsider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 20,013 Shares of StockAugust 21, 2025 | marketbeat.comRobert Allen III Sells 27,420 Shares of Invivyd (NASDAQ:IVVD) StockAugust 21, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) CFO Sells $16,896.51 in StockAugust 21, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) Insider Sells $16,896.51 in StockAugust 21, 2025 | marketbeat.comTimothy Edward Lee Sells 29,643 Shares of Invivyd (NASDAQ:IVVD) StockAugust 21, 2025 | marketbeat.comInsider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $21,678.80 in StockAugust 21, 2025 | marketbeat.comJill Andersen Sells 49,402 Shares of Invivyd (NASDAQ:IVVD) StockAugust 21, 2025 | marketbeat.comFY2028 Earnings Estimate for Invivyd Issued By HC WainwrightAugust 21, 2025 | marketbeat.comInvivyd stock falls after pricing capital raise of $50M via securities offeringAugust 21, 2025 | msn.comFY2028 Earnings Forecast for Invivyd Issued By HC WainwrightAugust 21, 2025 | americanbankingnews.comInvivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded WarrantsAugust 20, 2025 | globenewswire.comInvivyd announces common stock offering, no amount givenAugust 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVVD, FDMT, INBX, and CADL Company DescriptionsCandel Therapeutics NASDAQ:CADL$5.72 -0.24 (-3.95%) Closing price 03:59 PM EasternExtended Trading$5.70 -0.01 (-0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.4D Molecular Therapeutics NASDAQ:FDMT$6.73 -0.36 (-5.04%) Closing price 03:59 PM EasternExtended Trading$6.74 +0.01 (+0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Inhibrx Biosciences NASDAQ:INBX$25.00 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$25.02 +0.02 (+0.08%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Invivyd NASDAQ:IVVD$0.56 +0.04 (+7.09%) Closing price 03:59 PM EasternExtended Trading$0.56 +0.00 (+0.72%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Super Micro Computer Stock Hasn't Priced in Growth Yet Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Why Zuckerberg's META Sales Look More Bullish Than Bearish 3 Dividend Growth Leaders to Buy Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access